CATHERINE PHILLIPS

Issues related to R&D tax deductions and expense amortization Issues related to international taxation, including foreign-derived intangible income and interest deductions Issues related to supply chain incentives

Issues related to FDA and HHS program funding for the FY24 Labor, HHS, Education and Related Agencies, and FY24 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills Strategic National Stockpile (SNS) Funding and Oversight Funding for FDA e-labeling rule implementation Patient access to Part B medicines during the COVID-19 public health emergency Issues related to 340B program oversight Support for increased investments to address antimicrobial resistance. Deficit reduction, reconciliation

Issues related to Medicare and Medicaid coverage and reimbursement Issues related to the 340B Drug Discount Program Issues related to drug pricing Medicare reimbursement for biosimilars Issues related to CMMI

H.R.5260 - Reduced Costs and Continued Cures Act H.R. 5125 - the Strengthening Innovation in Medicare and Medicaid Act H.R. 5376 - Build Back Better Act -Issues related to Medicare and Medicaid coverage and reimbursement -Issues related to the 340B Drug Discount Program -Issues related to drug pricing -Medicare reimbursement for biosimilars -Issues related to CMMI

H.R. 2163/S. 464 - Safe Step Act H.R. 5376 - Build Back Better Act H.R. 5801 - Help Ensure Lower Patient (HELP) Copays Act -Drug pricing issues -Prescription Drug User Fee Act reauthorization -Issues related to prescription drug value -Issues related to the 340B Drug Discount Program

H.R. 2471 Consolidated Appropriations Act, FY2022 S.2076/H.R. 3932 PASTEUR Act H.R.7667 - Food and Drug Amendments of 2022 S.4348 - FDASLA Act of 2022 H.R.6963 - Accelerated Approval Integrity Act of 2022 H.R.6996 - Accelerating Access for Patients Act of 2022 H.R. 2565 / S.2952 the FDA Modernization Act H.R. 6972 - Give Kids a Chance Act H.R. 1730 - STAT Act H.R. 7032 - Increasing Transparency in Generic Drug Applications Act H.R. 5030/S. 2706 - DIVERSE Trials Act H.R. 6584 - DEPICT Act H.R.3085 - ENACT Act of 2021 -Issues related to public health protection including influenza development and preparedness -Issues related to antimicrobial and antiviral research and product development -Issues related to novel coronavirus and COVID-19 research and product development -Issues related to drug development including PDUFA and Cures 2.0

H.R. 1304, the American Innovation and R&D Competitiveness Act and S. 749 American Innovation and Jobs Act S.1260 - United States Innovation and Competition Act of 2021 -Issues related to R&D tax deductions and expense amortization -Issues related to international taxation, including foreign-derived intangible income and interest deductions -Issues related to supply chain incentives

Bills -H.R. 2617 Consolidated Appropriations Act, FY2023 Issues -Issues related to FDA and HHS program funding for the FY23 Labor, HHS, Education and Related Agencies, and FY22 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills -Strategic National Stockpile (SNS) Funding and Oversight -Funding for FDA e-labeling rule implementation -Patient access to Part B medicines during the COVID-19 public health emergency -Issues related to 340B program oversight -Support for increased investments to address antimicrobial resistance -Deficit reduction, reconciliation

H.R. 2471 Consolidated Appropriations Act, FY2022 S.2076/H.R. 3932 PASTEUR Act H.R.7667 - Food and Drug Amendments of 2022 S.4348 - FDASLA Act of 2022 H.R.6963 - Accelerated Approval Integrity Act of 2022 H.R.6996 - Accelerating Access for Patients Act of 2022 H.R. 2565 / S.2952 the FDA Modernization Act H.R. 6972 - Give Kids a Chance Act H.R. 1730 - STAT Act H.R. 7032 - Increasing Transparency in Generic Drug Applications Act H.R. 5030/S. 2706 - DIVERSE Trials Act H.R. 6584 - DEPICT Act H.R.3085 - ENACT Act of 2021 -Issues related to public health protection including influenza development and preparedness -Issues related to antimicrobial and antiviral research and product development -Issues related to novel coronavirus and COVID-19 research and product development -Issues related to drug development including PDUFA and Cures 2.0

H.R. 2163/S. 464 - Safe Step Act H.R. 5376 - Build Back Better Act H.R. 5801 - Help Ensure Lower Patient (HELP) Copays Act -Drug pricing issues -Prescription Drug User Fee Act reauthorization -Issues related to prescription drug value -Issues related to the 340B Drug Discount Program

H.R. 1304, the American Innovation and R&D Competitiveness Act and S. 749 American Innovation and Jobs Act S.1260 - United States Innovation and Competition Act of 2021 -Issues related to R&D tax deductions and expense amortization -Issues related to international taxation, including foreign-derived intangible income and interest deductions -Issues related to supply chain incentives

H.R. 2163/S. 464 - Safe Step Act S.1773 - Prescription Drug Pricing Dashboard Act H.R. 5376 - Build Back Better Act H.R. 3684- Infrastructure Investment and Jobs Act H.R. 5801 - Help Ensure Lower Patient (HELP) Copays Act S.2076/H.R. 3932 PASTEUR Act S. 3799- PREVENT Pandemics Act H.R.4521 - COMPETES Act of 2022 S.1260 - United States Innovation and Competition Act of 2021 H.R.6963 - Accelerated Approval Integrity Act of 2022 H.R.6996 - Accelerating Access for Patients Act of 2022 H.R. 2565 / S.2952 the FDA Modernization Act H.R. 6972 - Give Kids a Chance Act H.R. 1730 - STAT Act H.R. 7032 - Increasing Transparency in Generic Drug Applications Act H.R. 5030/S. 2706 - DIVERSE Trials Act H.R. 6584 - DEPICT Act -Issues related to the 340B Drug Discount Program -Issues relating to drug pricing -Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. -Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. -General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. -Issues related to healthcare legislation -Patient access to Part B medicines during the COVID-19 public health emergency -Issues related to health equity, diversity, and inclusion in clinical trials -Issues related to advanced development and procurement of medical countermeasures (MCMs) -Issues related to patient assistance and access -Issues relating to privacy and securing the data of and personal information of consumers -Issues relating to medical research data -Issues relating to screening and diagnostics -Issues related to public health preparedness and response

H.R. 2163/S. 464 - Safe Step Act S.1773 - Prescription Drug Pricing Dashboard Act H.R. 5376 - Build Back Better Act H.R. 3684- Infrastructure Investment and Jobs Act H.R. 5801 - Help Ensure Lower Patient (HELP) Copays Act S.2076/H.R. 3932 PASTEUR Act S. 3799- PREVENT Pandemics Act H.R.4521 - COMPETES Act of 2022 S.1260 - United States Innovation and Competition Act of 2021 H.R.6963 - Accelerated Approval Integrity Act of 2022 H.R.6996 - Accelerating Access for Patients Act of 2022 H.R. 2565 / S.2952 the FDA Modernization Act H.R. 6972 - Give Kids a Chance Act H.R. 1730 - STAT Act H.R. 7032 - Increasing Transparency in Generic Drug Applications Act H.R. 5030/S. 2706 - DIVERSE Trials Act H.R. 6584 - DEPICT Act -Issues related to the 340B Drug Discount Program -Issues relating to drug pricing -Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. -Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. -General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. -Issues related to healthcare legislation -Patient access to Part B medicines during the COVID-19 public health emergency -Issues related to health equity, diversity, and inclusion in clinical trials -Issues related to advanced development and procurement of medical countermeasures (MCMs) -Issues related to patient assistance and access -Issues relating to privacy and securing the data of and personal information of consumers -Issues relating to medical research data -Issues relating to screening and diagnostics -Issues related to public health preparedness and response

H.R. 2163/S. 464 - Safe Step Act H.R. 5376 - Build Back Better Act H.R. 5801 - Help Ensure Lower Patient (HELP) Copays Act -Drug pricing issues -Prescription Drug User Fee Act reauthorization -Issues related to prescription drug value -Issues related to the 340B Drug Discount Program

H.R. 1304, the American Innovation and R&D Competitiveness Act and S. 749 American Innovation and Jobs Act H.R. 5376 - Build Back Better Act H.R.4521 - COMPETES Act of 2022 S.1260 - United States Innovation and Competition Act of 2021 -Issues related to R&D tax deductions and expense amortization -Issues related to international taxation, including foreign-derived intangible income and interest deductions -Issues related to supply chain incentives

H.R.5260 - Reduced Costs and Continued Cures Act H.R. 5125 - the Strengthening Innovation in Medicare and Medicaid Act H.R. 5376 - Build Back Better Act S. 773/H.R. 3203 - [No official title] Related to The 340B Drug Discount Program -Issues related to Medicare and Medicaid coverage and reimbursement -Issues related to the 340B Drug Discount Program -Issues related to drug pricing -Medicare reimbursement for biosimilars -Issues related to CMMI

H.R. 2471 Consolidated Appropriations Act, FY2022 S.2076/H.R. 3932 PASTEUR Act H.R.____, the "Prescription Drug User Fee Amendments of 2022" S..____, the "Prescription Drug User Fee Amendments of 2022" H.R.6963 - Accelerated Approval Integrity Act of 2022 H.R.6996 - Accelerating Access for Patients Act of 2022 H.R. 2565 / S.2952 the FDA Modernization Act H.R. 6972 - Give Kids a Chance Act H.R. 1730 - STAT Act H.R. 7032 - Increasing Transparency in Generic Drug Applications Act H.R. 5030/S. 2706 - DIVERSE Trials Act H.R. 6584 - DEPICT Act -Issues related to public health protection including influenza development and preparedness -Issues related to antimicrobial and antiviral research and product development -Issues related to novel coronavirus and COVID-19 research and product development -Issues related to drug development including PDUFA and Cures 2.0

H.R. 1304, the American Innovation and R&D Competitiveness Act and S. 749 American Innovation and Jobs Act H.R. 5376 - Build Back Better Act H.R.4521 - COMPETES Act of 2022 S.1260 - United States Innovation and Competition Act of 2021 -Issues related to R&D tax deductions and expense amortization -Issues related to international taxation, including foreign-derived intangible income and interest deductions -Issues related to supply chain incentives

H.R. 5402 - FY 2022 Labor, HHS, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022 H.R. 5305 Extending Government Funding and Delivering Emergency Assistance Act H.R. 2471 Consolidated Appropriations Act, FY2022 -Issues related to FDA and HHS program funding for the FY22 Labor, HHS, Education and Related Agencies, and FY22 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills -Strategic National Stockpile (SNS) Funding and Oversight -Funding for FDA e-labeling rule implementation -Patient access to Part B medicines during the COVID-19 public health emergency -Issues related to 340B program oversight -Support for increased investments to address antimicrobial resistance. -Deficit reduction, reconciliation

none

S.2782 - National Defense Authorization Act for Fiscal Year 2022 H.R.4350 - National Defense Authorization Act for Fiscal Year 2022 -Issues related to pharmaceutical supply chains and related security issues

H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) S.551, REFUND Act of 2019 H.R. 1499, the Protecting Consumer Access to Generic Drugs Act S. 3013, Encouraging Innovative Benefit Design to Lower Costs for Seniors Act H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act H.R. 1319, The American Rescue Plan of 2021 S. 920 - The Affordable and Safe Prescription Drug Importation Act S. 909 - The Prescription Drug Price Relief Act S. 908 - The Medicare Drug Price Negotiation Act S.4796, The Fair Care Act of 2020 S. 2428- False Claims Amendments Act of 2021 S.1773 - Prescription Drug Pricing Dashboard Act H.R.5260 - Reduced Costs and Continued Cures Act H.R. 5125, the Strengthening Innovation in Medicare and Medicaid Act H.R. 5376 - Build Back Better Act -Issues related to Medicare and Medicaid coverage and reimbursement -Issues related to the 340B Drug Discount Program -Issues related to drug pricing -Medicare reimbursement for biosimilars -MACRA treatment and reimbursement of Part B drugs -Medicare payments for inpatient antimicrobials -Issues related to drug importation -Issues related to the International Pricing Index for Medicare Part B and general reference pricing -Issues related to CMMI

H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) H.R. 2113 - The Prescription Drug STAR Act H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 4199, Prescription Drug Pricing Reduction Act of 2020 S.551 - REFUND Act of 2019 S.1712/H.R.4100 - DISARM Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 2163/S. 464 - Safe Step Act S.4796, The Fair Care Act of 2020 S.2076/H.R. 3932 PASTEUR Act S.1773 - Prescription Drug Pricing Dashboard Act S. 773/H.R. 3203 - [No official title] Related to The 340B Drug Discount Program S. 658- ADAPT Act- Accelerated Drug Approval for Prescription Therapies H.R.5260 - Reduced Costs and Continued Cures Act H.R. 5376 - Build Back Better Act H.R. 3684- Infrastructure Investment and Jobs Act H.R. 5030/S. 2706 - DIVERSE Trials Act H.R. 5801 - Help Ensure Lower Patient (HELP) Copays Act -Issues related to the 340B Drug Discount Program -Issues relating to drug pricing -Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. -Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. -General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. -Issues related to healthcare legislation -Patient access to Part B medicines during the COVID-19 public health emergency -Issues related to health equity, diversity, and inclusion in clinical trials -Issues related to advanced development and procurement of medical countermeasures (MCMs) -Issues related to patient assistance and access -Issues relating to privacy and securing the data of and personal information of consumers -Issues relating to medical research data -Issues relating to screening and diagnostics

S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act H.R.133 - Consolidated Appropriations Act, 2021 S.2076/H.R. 3932 PASTEUR Act -Issues related to public health protection including influenza development and preparedness -Issues related to antimicrobial and antiviral research and product development -Issues related to novel coronavirus and COVID-19 research and product development -Issues related to drug development including PDUFA and Cures 2.0

H.R. 1304, the American Innovation and R&D Competitiveness Act and -Issues related to R&D tax deductions and expense amortization -Issues related to supply chain incentives -Issues related to corporate tax rate as well as international taxation, including foreign-derived intangible income

S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) S.551, REFUND Act of 2019 S.4796, The Fair Care Act of 2020 H.R.5260 - Reduced Costs and Continued Cures Act - Drug pricing issues - Prescription Drug User Fee Act reauthorization - Issues related to prescription drug value - Issues related to the 340B Drug Discount Program

H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 S.Con.Res 14- FY2022 Budget Resolution H.R. 1319 - American Rescue Plan Act, 2021 H.R. 5402 - FY 2022 Labor, HHS, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022 H.R. 5305 Extending Government Funding and Delivering Emergency Assistance Act - Issues related to FDA and HHS program funding for the FY22 Labor, HHS, Education and Related Agencies, and FY22 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills - Strategic National Stockpile (SNS) Funding and Oversight - Funding for FDA e-labeling rule implementation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to 340B program oversight - Support for increased investments to address antimicrobial resistance. - Deficit reduction, reconciliation

Foreign Investment Risk Review Modernization Act (FIRRMA) H.R. 5841/S. 2098 ​legislation that would reform the Committee on Foreign Investment in the United States (CFIUS)

H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) S.551, REFUND Act of 2019 H.R. 1499, the Protecting Consumer Access to Generic Drugs Act S. 3013, Encouraging Innovative Benefit Design to Lower Costs for Seniors Act H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act H.R. 1319, The American Rescue Plan of 2021 H.R./S. XX American Jobs Plan S. 920 - The Affordable and Safe Prescription Drug Importation Act S. 909 - The Prescription Drug Price Relief Act S. 908 - The Medicare Drug Price Negotiation Act S.4796, The Fair Care Act of 2020 S.1773 - Prescription Drug Pricing Dashboard Act H.R.5260 - Reduced Costs and Continued Cures Act H.R. 5125, the Strengthening Innovation in Medicare and Medicaid Act H.R. 5376 - Build Back Better Act - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B and general reference pricing - Issues related to CMMI

S.2782 - National Defense Authorization Act for Fiscal Year 2022 H.R.4350 - National Defense Authorization Act for Fiscal Year 2022 - Issues related to pharmaceutical supply chains and related security issues

H.R. 1304, the American Innovation and R&D Competitiveness Act and S. 749 American Innovation and Jobs Act - Issues related to R&D tax deductions and expense amortization - Issues related to supply chain incentives - Issues related to corporate tax rate as well as international taxation, including foreign-derived intangible income

S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act H.R.133 - Consolidated Appropriations Act, 2021 S.2076/H.R. 3932 PASTEUR Act - Issues related to public health protection including influenza development and preparedness - Issues related to antimicrobial and antiviral research and product development - Issues related to novel coronavirus and COVID-19 research and product development - Issues related to drug development including PDUFA and Cures 2.0

S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. S.551, REFUND Act of 2019 HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program S.4796, The Fair Care Act of 2020 - Drug pricing issues - Prescription Drug User Fee Act reauthorization - Issues related to prescription drug value

S.4049 - National Defense Authorization Act for Fiscal Year 2021 H.R.2500 - National Defense Authorization Act for Fiscal Year 2021 H.R. 6395, William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 - Issues related to pharmaceutical supply chains and related security issues

H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R. 3 - Lower Drug Costs Now Act of 2019 H.R.19, Lower Costs, More Cures Act of 2019 H.R. 2113 - The Prescription Drug STAR Act H.R. 1520, the Purple Book H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019 S.551 - REFUND Act of 2019 S.4760, The Pioneering Antimicrobial Subscriptions To End Up Surging Resistance Act of 2020 S.1712/H.R.4100 - DISARM Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act H.R. 1319 , American Rescue Plan Act of 2021 H.R. xx - Safe Step Act (no bill number yet) S.4796, The Fair Care Act of 2020 H.R.1966/S.946 - Henrietta Lacks Enhancing Cancer Research Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021, 116th Congress (2019-2020) S. 4626, SAFE DATA Act S. 3456, Consumer Data Privacy and Security Act H.R. 2013, Information Transparency & Personal Data Control Act S. 2968, Consumer Online Privacy Rights Act - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to diversity in clinical trials - Issues related to advanced development and procurement of medical countermeasures (MCMs) - Issues relating to privacy and securing the data of and personal information of consumers - Issues relating to medical research data

H.R. 3 - Lower Drug Costs Now Act of 2019 H.R.19, Lower Costs, More Cures Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019 S.977 - Transparent Drug Pricing Act of 2019 S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act S. 3013, Encouraging Innovative Benefit Design to Lower Costs for Seniors Act H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act H.R. 1319, The American Rescue Plan of 2021 H.R./S. XX American Jobs Plan S. 920 - The Affordable and Safe Prescription Drug Importation Act S. 909 - The Prescription Drug Price Relief Act S. 908 - The Medicare Drug Price Negotiation Act S.4796, The Fair Care Act of 2020 - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B and general reference pricing - Issues related to CMMI

- Foreign Investment Risk Review Modernization Act (FIRRMA) H.R. 5841/S. 2098 ​legislation that would reform the Committee on Foreign Investment in the United States (CFIUS)

H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 8337 - Continuing Appropriations Act of 2021 H.R. 1319 - American Rescue Plan Act, 2021 H.R. XX - FY 2022 Labor, HHS, Education and Related Agencies Appropriations H.R. XX - FY 2022 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation - Issues related to FDA and HHS program funding for the FY22 Labor, HHS, Education and Related Agencies, and FY22 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills - Strategic National Stockpile (SNS) Funding and Oversight - Funding for FDA e-labeling rule implementation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to 340B program oversight

H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) S.1895, Lower Health Care Costs Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019 S.977 - Transparent Drug Pricing Act of 2019 S.551, REFUND Act of 2019 H.R. 1499, the Protecting Consumer Access to Generic Drugs Act S. 3013, Encouraging Innovative Benefit Design to Lower Costs for Seniors Act H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act H.R. 1319, The American Rescue Plan of 2021 H.R./S. XX American Jobs Plan S. 920 - The Affordable and Safe Prescription Drug Importation Act S. 909 - The Prescription Drug Price Relief Act S. 908 - The Medicare Drug Price Negotiation Act S.4796, The Fair Care Act of 2020 S.1773 - Prescription Drug Pricing Dashboard Act - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B and general reference pricing - Issues related to CMMI

H.R. 3788, the Protecting American Innovation Act - Issues relating to trade policy and negotiations impacting the biopharmaceutical industry including the TRIPS IP Waiver - Issues related to the United States-Mexico-Canada Agreement - Issues related to other Free Trade Agreements (UK, Kenya, Chile, Colombia, Peru, CAFTA-DR) - Issues related to compulsory licensing of foriegn patents - Issues related to WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS)

H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) H.R. 2113 - The Prescription Drug STAR Act H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 4199, Prescription Drug Pricing Reduction Act of 2020 S.551 - REFUND Act of 2019 S.1712/H.R.4100 - DISARM Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 2163/S. 464 - Safe Step Act S.4796, The Fair Care Act of 2020 S.2076/H.R. 3932 PASTEUR Act S.1773 - Prescription Drug Pricing Dashboard Act S. 773/H.R. 3203 - [No official title] Related to The 340B Drug Discount Program S. 4626, SAFE DATA Act S. 3456, Consumer Data Privacy and Security Act H.R. 2013, Information Transparency & Personal Data Control Act S. 2968, Consumer Online Privacy Rights Act S. 3300, Data Protection Act of 2021 H.R.3801, Data Localization Compendium Legislation - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to diversity in clinical trials - Issues related to advanced development and procurement of medical countermeasures (MCMs) - Issues related to patient assistance and acces - Issues relating to privacy and securing the data of and personal information of consumers - Issues relating to medical research data

H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 8337 - Continuing Appropriations Act of 2021 H.R. 1319 - American Rescue Plan Act, 2021 H.R. XX - FY 2022 Labor, HHS, Education and Related Agencies Appropriations H.R. XX - FY 2022 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation - Issues related to FDA and HHS program funding for the FY22 Labor, HHS, Education and Related Agencies, and FY22 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills - Strategic National Stockpile (SNS) Funding and Oversight - Funding for FDA e-labeling rule implementation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to 340B program oversight

S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) S.551, REFUND Act of 2019 HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program S.4796, The Fair Care Act of 2020 - Drug pricing issues - Prescription Drug User Fee Act reauthorization - Issues related to prescription drug value

S. 2852 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 S. 3548 - CARES Act (Coronavirus Stimulus 3) S.4760, The Pioneering Antimicrobial Subscriptions To End Up Surging Resistance Act of 2020 H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act H.R.133 - Consolidated Appropriations Act, 2021 - Issues related to public health protection including influenza development and preparedness - Issues related to antimicrobial and antiviral research and product development - Issues related to novel coronavirus and COVID-19 research and product development - Issues related to drug development including PDUFA and Cures 2.0

H.R. 3 - Lower Drug Costs Now Act of 2019 H.R.19, Lower Costs, More Cures Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019 S.977 - Transparent Drug Pricing Act of 2019 S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act S. 3013, Encouraging Innovative Benefit Design to Lower Costs for Seniors Act H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act H.R. 1319, The American Rescue Plan of 2021 H.R./S. XX American Jobs Plan S. 920 - The Affordable and Safe Prescription Drug Importation Act S. 909 - The Prescription Drug Price Relief Act S. 908 - The Medicare Drug Price Negotiation Act S.4796, The Fair Care Act of 2020 - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B and general reference pricing - Issues related to CMMI

H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R. 3 - Lower Drug Costs Now Act of 2019 H.R.19, Lower Costs, More Cures Act of 2019 H.R. 2113 - The Prescription Drug STAR Act H.R. 1520, the Purple Book H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019 S.551 - REFUND Act of 2019 S.4760, The Pioneering Antimicrobial Subscriptions To End Up Surging Resistance Act of 2020 S.1712/H.R.4100 - DISARM Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act H.R. 1319 , American Rescue Plan Act of 2021 H.R. xx - Safe Step Act (no bill number yet) S.4796, The Fair Care Act of 2020 H.R.1966/S.946 - Henrietta Lacks Enhancing Cancer Research Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021, 116th Congress (2019-2020) S. 4626, SAFE DATA Act S. 3456, Consumer Data Privacy and Security Act H.R. 2013, Information Transparency & Personal Data Control Act S. 2968, Consumer Online Privacy Rights Act - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to diversity in clinical trials - Issues related to advanced development and procurement of medical countermeasures (MCMs) - Issues relating to privacy and securing the data of and personal information of consumers - Issues relating to medical research data

S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. S.551, REFUND Act of 2019 HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program S.4796, The Fair Care Act of 2020 - Drug pricing issues - Prescription Drug User Fee Act reauthorization - Issues related to prescription drug value

H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 8337 - Continuing Appropriations Act of 2021 H.R. 1319 - American Rescue Plan Act, 2021 H.R. XX - FY 2022 Labor, HHS, Education and Related Agencies Appropriations H.R. XX - FY 2022 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation - Issues related to FDA and HHS program funding for the FY22 Labor, HHS, Education and Related Agencies, and FY22 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills - Strategic National Stockpile (SNS) Funding and Oversight - Funding for FDA e-labeling rule implementation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to 340B program oversight

Foreign Investment Risk Review Modernization Act (FIRRMA) H.R. 5841/S. 2098 ​legislation that would reform the Committee on Foreign Investment in the United States (CFIUS)

H.R. 6443, Securing the National Supply Chain Act H.R. 6630, Securing Americas Critical Minerals Supply Chain Act H.R. 6690, Bring Entrepreneurial Advancements To Consumers Here In North America Act H.R. 6713, Furthering Our Recovery With American Research and Development H.R. 6863, COVID-19 Accountability Act H.R. 6903, Bring American Companies Home Act H.R. 6930, To mitigate drug shortages and provide incentives for maintaining, expanding, and relocating the manufacturing of active pharmaceutical ingredients, excipients, medical diagnostic devices, pharmaceuticals, and personal protective equipment in the United States, and for other purposes. H.R. 7505, American Innovation Act H.R. 7527, To rescue domestic medical manufacturing activity by providing incentives in economically distressed areas of the United States and its possessions. H.R. 7537, Infectious Disease Therapies Research and Innovation Act H.R. 7555, More Cures Act H.R. 7556, Start-ups for Cures Act S. 3593, Furthering Our Recovery With American Research and Development S. 3945, Bring Entrepreneurial Advancements to Consumers Here In North America (BEAT CHINA) Act S. 3827, Medical Supplies for Pandemics Act H.R. 4710, Pharmaceutical Independence Long-Term Readiness Reform Act H.R. 6731, Securing Americas Pharmaceutical Supply Chain Act S. 3432, Securing Americas Medicine Cabinet [SAM-C] Act S. 3478, Commission on Americas Medical Security Act S. 3538, Strengthening America's Supply Chain and National Security Act S. 3635, Protecting our Pharmaceutical Supply Chain from China Act (previously S. 3537) H.R. 6531, Medical Supplies for Pandemics Act H.R. 6876, To amend the Public Health Service Act to ensure that the contents of the Strategic National Stockpile remain in good working order and, as appropriate, conduct maintenance services on contents of the stockpile, and for other purposes. H.R. 6049, Medical Supply Chain Security Act H.R. 6062 - to amend certain provisions in the Federal Food, Drug, and Cosmetic Act relating to the discontinuance or interruption in the production of life-saving drugs so as to apply such provisions with respect to life-saving devices, and for other purposes H.R. 6080, Preventing Drug Shortages Act H.R. 6393, Strengthening America's Supply Chain and National Security Act H.R. 6660, Limit Ongoing Shortages and Stabilize Supply Act H.R. 6670, Prescription for American Drug Independence Act H.R. 6708, Securing Americas Medicine Cabinet Act H.R. 6885, Safe and Secure Medicine Supply for Hardworking Americans Act S. 2723, Mitigating Emergency Drug Shortages Act S. 3343, Medical Supply Chain Security Act S. 3780, Help Onshore Manufacturing Efficiencies for Drugs and Devices Act (HOME) Act S. 3781, Pharmaceutical Accountability, Responsibility, and Transparency (PART) Act S. 3942, Securing Americas Medical Supply Chain and Advancing the Production of Life Saving Medicines Act H.R. 6395, William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 - Issues related to pharmaceutical supply chains - Issues related to reporting on location of origin of pharmaceutical products - Issues related to drug shortages - Issues related to pharmaceutical manufacturing

H.R.3 - Lower Drug Costs Now Act of 2019 S.977 - Transparent Drug Pricing Act of 2019 S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act H.R. 965, the CREATES Act H.R.269/S.1379, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22). S.1895, Lower Health Care Costs Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019. H.R.19, Lower Costs, More Cures Act of 2019. S. 3013, Encouraging Innovative Benefit Design to Lowes Costs for Seniors Act S. 3129, Lower Cost, More Cures Act of 2019 H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B - Issues related to CMMI

H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019; H.R.6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (P.L.115-245) S. 3158, Department of Labor, Health & Human Services, and Education, and Related Agencies Appropriations Act of 2019; H.J.Res.31, Consolidated Appropriations Act, 2019 (P.L.116-6); FY 2020 H.R.3164, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure. H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020 and the FY2020 Consolidated measure. Reimbursement and vial size issues. H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.133 - Consolidated Appropriations Act, 2021 H.R. 4378 - Continuing Appropriations Act and Health Extenders Act H.R. 133 - Consolidated Appropriations Act, 2021 H.R. 8337 - Continuing Appropriations Act of 2021 - Issues related to FDA and HHS program funding for the FY20 Labor, HHS, Education and Related Agencies, and FY20 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills - Strategic National Stockpile (SNS) Funding and Oversight - Patient access to Part B medicines during the COVID-19 public health emergency

S. 2852 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act (No bill number yet) H.R.133 - Consolidated Appropriations Act, 2021 - Issues related to public health protection including influenza development and preparedness - Issues related to antimicrobial and antiviral research and product development - Issues related to novel coronavirus and COVID-19 research and product development

S.4049 - National Defense Authorization Act for Fiscal Year 2021 H.R.2500 - National Defense Authorization Act for Fiscal Year 2021 H.R. 6395, William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 - Issues related to pharmaceutical supply chains and related security issues

S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. S.551, REFUND Act of 2019 HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program - Drug pricing issues - Prescription Drug User Fee Act reauthorization - Issues related to prescription drug value

H.R.2209 - Fixing Global Freeloading Act - Issues relating to trade policy and negotiations impacting the biopharmaceutical industry - Issues related to the United States-Mexico-Canada Agreement - Issues related to other Free Trade Agreements (Chile, Colombia, Peru, CAFTA-DR)

H.R.4549 - American Innovation and Competitiveness Act of 2019 - Issues related to the tax reform bill and implementation - Issues related to supply chain incentives

S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. S.551, REFUND Act of 2019 HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program - Drug pricing issues - Prescription Drug User Fee Act reauthorization - Issues related to prescription drug value

H.R.3 - Lower Drug Costs Now Act of 2019 S.977 - Transparent Drug Pricing Act of 2019 S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act H.R. 965, the CREATES Act H.R.269/S.1379, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22). S.1895, Lower Health Care Costs Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019. H.R.19, Lower Costs, More Cures Act of 2019. S. 3013, Encouraging Innovative Benefit Design to Lowes Costs for Seniors Act S. 3129, Lower Cost, More Cures Act of 2019 H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act -Issues related to Medicare and Medicaid coverage and reimbursement -Issues related to the 340B Drug Discount Program -Issues related to drug pricing -Medicare reimbursement for biosimilars -MACRA treatment and reimbursement of Part B drugs -Medicare payments for inpatient antimicrobials -Issues related to drug importation -Issues related to the International Pricing Index for Medicare Part B -Issues related to CMMI

S.4049 - National Defense Authorization Act for Fiscal Year 2021 H.R.2500 - National Defense Authorization Act for Fiscal Year 2021 H.R. 6395, William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 - Issues related to pharmaceutical supply chains and related security issues

S. 2852 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act (No bill number yet) - Issues related to public health protection including influenza development and preparedness - Issues related to antimicrobial and antiviral research and product development - Issues related to novel coronavirus and COVID-19 research and product development

H.R. 6443, Securing the National Supply Chain Act H.R. 6630, Securing Americas Critical Minerals Supply Chain Act H.R. 6690, Bring Entrepreneurial Advancements To Consumers Here In North America Act H.R. 6713, Furthering Our Recovery With American Research and Development H.R. 6863, COVID-19 Accountability Act H.R. 6903, Bring American Companies Home Act H.R. 6930, To mitigate drug shortages and provide incentives for maintaining, expanding, and relocating the manufacturing of active pharmaceutical ingredients, excipients, medical diagnostic devices, pharmaceuticals, and personal protective equipment in the United States, and for other purposes. H.R. 7505, American Innovation Act H.R. 7527, To rescue domestic medical manufacturing activity by providing incentives in economically distressed areas of the United States and its possessions. H.R. 7537, Infectious Disease Therapies Research and Innovation Act H.R. 7555, More Cures Act H.R. 7556, Start-ups for Cures Act S. 3593, Furthering Our Recovery With American Research and Development S. 3945, Bring Entrepreneurial Advancements to Consumers Here In North America (BEAT CHINA) Act S. 3827, Medical Supplies for Pandemics Act H.R. 4710, Pharmaceutical Independence Long-Term Readiness Reform Act H.R. 6731, Securing Americas Pharmaceutical Supply Chain Act S. 3432, Securing Americas Medicine Cabinet [SAM-C] Act S. 3478, Commission on Americas Medical Security Act S. 3538, Strengthening America's Supply Chain and National Security Act S. 3635, Protecting our Pharmaceutical Supply Chain from China Act (previously S. 3537) H.R. 6531, Medical Supplies for Pandemics Act H.R. 6876, To amend the Public Health Service Act to ensure that the contents of the Strategic National Stockpile remain in good working order and, as appropriate, conduct maintenance services on contents of the stockpile, and for other purposes. H.R. 6049, Medical Supply Chain Security Act H.R. 6062 - to amend certain provisions in the Federal Food, Drug, and Cosmetic Act relating to the discontinuance or interruption in the production of life-saving drugs so as to apply such provisions with respect to life-saving devices, and for other purposes H.R. 6080, Preventing Drug Shortages Act H.R. 6393, Strengthening America's Supply Chain and National Security Act H.R. 6660, Limit Ongoing Shortages and Stabilize Supply Act H.R. 6670, Prescription for American Drug Independence Act H.R. 6708, Securing Americas Medicine Cabinet Act H.R. 6885, Safe and Secure Medicine Supply for Hardworking Americans Act S. 2723, Mitigating Emergency Drug Shortages Act S. 3343, Medical Supply Chain Security Act S. 3780, Help Onshore Manufacturing Efficiencies for Drugs and Devices Act (HOME) Act S. 3781, Pharmaceutical Accountability, Responsibility, and Transparency (PART) Act S. 3942, Securing Americas Medical Supply Chain and Advancing the Production of Life Saving Medicines Act H.R. 6395, William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 - Issues related to pharmaceutical supply chains - Issues related to reporting on location of origin of pharmaceutical products - Issues related to drug shortages - Issues related to pharmaceutical manufacturing

H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019; H.R.6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (P.L.115-245) S. 3158, Department of Labor, Health & Human Services, and Education, and Related Agencies Appropriations Act of 2019; H.J.Res.31, Consolidated Appropriations Act, 2019 (P.L.116-6); FY 2020 H.R.3164, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure. H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020 and the FY2020 Consolidated measure. Reimbursement and vial size issues. H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act S. 3548 - CARES Act (Coronavirus Stimulus 3) - Issues related to FDA and HHS program funding for the FY20 Labor, HHS, Education and Related Agencies, and FY20 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills - Strategic National Stockpile (SNS) Funding and Oversight - Patient access to Part B medicines during the COVID-19 public health emergency

S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. S.551, REFUND Act of 2019 HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program - Drug pricing issues - Prescription Drug User Fee Act reauthorization - Issues related to prescription drug value

S.659 - Biologic Patent Transparency Act S. 1227, Prescription Pricing for the People Act of 2019 S. 1224, Stop STALLING Act S.1416 - Affordable Prescriptions for Patients Act of 2019 H.R. 7296, Medications Affordable by Preventing Pandemic Price Gouging Act (MMAPPP) Act of 2020 H.R. 7288 Taxpayer Research and Coronavirus Knowledge (TRACK) Act - Intellectual property and process patent issues - Patent litigation reform - IPR process - Section 101 Reform - Compulsory licensing issues

S. 2852 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act - Issues related to public health protection including influenza development and preparedness - Issues related to antimicrobial and antiviral research and product development - Issues related to novel coronavirus and COVID-19 research and product development

H.R.2209 - Fixing Global Freeloading Act - Issues relating to trade policy and negotiations impacting the biopharmaceutical industry - Issues related to the United States-Mexico-Canada Agreement

S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act H.R.4100 - DISARM Act of 2019 S.340- CREATES Act of 2019 H.R. 2113 - The Prescription Drug STAR Act H.R. 1520, the Purple Book H.R. 1499, the Protecting Cok Continuity Act; H.R. 1503, the Orange Book Transparency Act;consumer Access to Generic Drugs Act; and H.R. 965, the CREATES Act; H.R.3: Lower Drug Costs Now Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S.551, REFUND Act of 2019 H.R. 6443, Securing the National Supply Chain Act H.R. 6630, Securing Americas Critical Minerals Supply Chain Act H.R. 6690, Bring Entrepreneurial Advancements To Consumers Here In North America Act H.R. 6713, Furthering Our Recovery With American Research and Development H.R. 6863, COVID-19 Accountability Act H.R. 6903, Bring American Companies Home Act H.R. 6930, To mitigate drug shortages and provide incentives for maintaining, expanding, and relocating the manufacturing of active pharmaceutical ingredients, excipients, medical diagnostic devices, pharmaceuticals, and personal protective equipment in the United States, and for other purposes. H.R. 7505, American Innovation Act H.R. 7527, To rescue domestic medical manufacturing activity by providing incentives in economically distressed areas of the United States and its possessions. H.R. 7537, Infectious Disease Therapies Research and Innovation Act H.R. 7555, More Cures Act H.R. 7556, Start-ups for Cures Act S. 3593, Furthering Our Recovery With American Research and Development S. 3945, Bring Entrepreneurial Advancements to Consumers Here In North America (BEAT CHINA) Act S. 3827, Medical Supplies for Pandemics Act H.R. 4710, Pharmaceutical Independence Long-Term Readiness Reform Act H.R. 6731, Securing Americas Pharmaceutical Supply Chain Act S. 3432, Securing Americas Medicine Cabinet [SAM-C] Act S. 3478, Commission on Americas Medical Security Act S. 3538, Strengthening America's Supply Chain and National Security Act S. 3635, Protecting our Pharmaceutical Supply Chain from China Act (previously S. 3537) H.R. 6531, Medical Supplies for Pandemics Act H.R. 6876, To amend the Public Health Service Act to ensure that the contents of the Strategic National Stockpile remain in good working order and, as appropriate, conduct maintenance services on contents of the stockpile, and for other purposes. H.R. 6049, Medical Supply Chain Security Act H.R. 6062 - to amend certain provisions in the Federal Food, Drug, and Cosmetic Act relating to the discontinuance or interruption in the production of life-saving drugs so as to apply such provisions with respect to life-saving devices, and for other purposes H.R. 6080, Preventing Drug Shortages Act H.R. 6393, Strengthening America's Supply Chain and National Security Act H.R. 6660, Limit Ongoing Shortages and Stabilize Supply Act H.R. 6670, Prescription for American Drug Independence Act H.R. 6708, Securing Americas Medicine Cabinet Act H.R. 6885, Safe and Secure Medicine Supply for Hardworking Americans Act S. 2723, Mitigating Emergency Drug Shortages Act S. 3343, Medical Supply Chain Security Act S. 3780, Help Onshore Manufacturing Efficiencies for Drugs and Devices Act (HOME) Act S. 3781, Pharmaceutical Accountability, Responsibility, and Transparency (PART) Act S. 3942, Securing Americas Medical Supply Chain and Advancing the Production of Life Saving Medicines Act - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency Medical Supply Chain - Issues related to pharmaceutical supply chains - Issues related to reporting on location of origin of pharmaceutical products - Issues related to drug shortages - Issues related to pharmaceutical manufacturing

- Foreign Investment Risk Review Modernization Act (FIRRMA) H.R. 5841/S. 2098 legislation that would reform the Committee on Foreign Investment in the United States (CFIUS)

S.4049 - National Defense Authorization Act for Fiscal Year 2021 H.R.2500 - National Defense Authorization Act for Fiscal Year 2021 - Issues related to pharmaceutical supply chains and related security issues

- Issues related to the tax reform bill and implementation - Issues related to supply chain incentives

H.R.3 - Lower Drug Costs Now Act of 2019 S.977 - Transparent Drug Pricing Act of 2019 S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act H.R. 965, the CREATES Act H.R.269/S.1379, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22). S.1895, Lower Health Care Costs Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019. H.R.19, Lower Costs, More Cures Act of 2019. S. 3013, Encouraging Innovative Benefit Design to Lowes Costs for Seniors Act S. 3129, Lower Cost, More Cures Act of 2019 H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B - Issues related to CMMI

S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. S.551, REFUND Act of 2019 - Drug pricing issues - Prescription Drug User Fee Act reauthorization - HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program - Issues related to prescription drug value

H.R.3 - Lower Drug Costs Now Act of 2019 S.977 - Transparent Drug Pricing Act of 2019 S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act H.R. 965, the CREATES Act H.R.269/S.1379, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22). S.1895, Lower Health Care Costs Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019. H.R.19, Lower Costs, More Cures Act of 2019. S. 3013, Encouraging Innovative Benefit Design to Lowes Costs for Seniors Act S. 3129, Lower Cost, More Cures Act of 2019 H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B - Issues related to CMMI

H.R.2209 - Fixing Global Freeloading Act - Issues relating to trade policy and negotiations impacting the biopharmaceutical industry - Issues related to the United States-Mexico-Canada Agreement

- Issues related to the tax reform bill and implementation - Issues related to supply chain incentives

H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019; H.R.6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (P.L.115-245) S. 3158, Department of Labor, Health & Human Services, and Education, and Related Agencies Appropriations Act of 2019; H.J.Res.31, Consolidated Appropriations Act, 2019 (P.L.116-6); FY 2020 H.R.3164, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure. H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020 and the FY2020 Consolidated measure. Reimbursement and vial size issues. H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act S. 3548 - CARES Act (Coronavirus Stimulus 3) - Issues related to FDA and HHS program funding for the FY20 Labor, HHS, Education and Related Agencies, and FY20 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills - Strategic National Stockpile (SNS) Funding and Oversight - Patient access to Part B medicines during the COVID-19 public health emergency

S.659 - Biologic Patent Transparency Act S. 1227, Prescription Pricing for the People Act of 2019 S. 1224, Stop STALLING Act S.1416 - Affordable Prescriptions for Patients Act of 2019 - Issues related to Intellectual property and process patent - Patent litigation reform - IPR process - Section 101 Reform - Compulsory licensing issues

- Issues related to Foreign Agents Registration Act (FARA including Disclosing Foreign Influence Act -H.R. 4170/S. 2039

S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act H.R.4100 - DISARM Act of 2019 S.340- CREATES Act of 2019 H.R. 2113 - The Prescription Drug STAR Act H.R. 1520, the Purple Book H.R. 1499, the Protecting Cok Continuity Act; H.R.3: Lower Drug Costs Now Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S.551, REFUND Act of 2019 S.4760, The Pioneering Antimicrobial Subscriptions To End Up Surging Resistance Act of 2020 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act (HCR) S. 4626, SAFE DATA Act S. 3456, Consumer Data Privacy and Security Act H.R. 2013, Information Transparency & Personal Data Control Act S. 2968, Consumer Online Privacy Rights Ac - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues relating to privacy and securing the data of and personal information of consumers - Issues relating to medical research data

S.4049 - National Defense Authorization Act for Fiscal Year 2021 H.R.2500 - National Defense Authorization Act for Fiscal Year 2021 H.R. 6395, William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 - Issues related to pharmaceutical supply chains and related security issues

S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. S.551, REFUND Act of 2019 HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program - Drug pricing issues - Prescription Drug User Fee Act reauthorization - Issues related to prescription drug value

Foreign Investment Risk Review Modernization Act (FIRRMA) H.R. 5841/S. 2098 ​legislation that would reform the Committee on Foreign Investment in the United States (CFIUS)

H.R.2209 - Fixing Global Freeloading Act - Issues relating to trade policy and negotiations impacting the biopharmaceutical industry - Issues related to the United States-Mexico-Canada Agreement - Issues related to other Free Trade Agreements (UK, Kenya, Chile, Colombia, Peru, CAFTA-DR) - Issues related to compulsory licensing of foriegn patents

S. 2852 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act (No bill number yet) H.R.133 - Consolidated Appropriations Act, 2021 - Issues related to public health protection including influenza development and preparedness - Issues related to antimicrobial and antiviral research and product development - Issues related to novel coronavirus and COVID-19 research and product development

H.R. 6443, Securing the National Supply Chain Act H.R. 6630, Securing Americas Critical Minerals Supply Chain Act H.R. 6690, Bring Entrepreneurial Advancements To Consumers Here In North America Act H.R. 6713, Furthering Our Recovery With American Research and Development H.R. 6863, COVID-19 Accountability Act H.R. 6903, Bring American Companies Home Act H.R. 6930, To mitigate drug shortages and provide incentives for maintaining, expanding, and relocating the manufacturing of active pharmaceutical ingredients, excipients, medical diagnostic devices, pharmaceuticals, and personal protective equipment in the United States, and for other purposes. H.R. 7505, American Innovation Act H.R. 7527, To rescue domestic medical manufacturing activity by providing incentives in economically distressed areas of the United States and its possessions. H.R. 7537, Infectious Disease Therapies Research and Innovation Act H.R. 7555, More Cures Act H.R. 7556, Start-ups for Cures Act S. 3593, Furthering Our Recovery With American Research and Development S. 3945, Bring Entrepreneurial Advancements to Consumers Here In North America (BEAT CHINA) Act S. 3827, Medical Supplies for Pandemics Act H.R. 4710, Pharmaceutical Independence Long-Term Readiness Reform Act H.R. 6731, Securing Americas Pharmaceutical Supply Chain Act S. 3432, Securing Americas Medicine Cabinet [SAM-C] Act S. 3478, Commission on Americas Medical Security Act S. 3538, Strengthening America's Supply Chain and National Security Act S. 3635, Protecting our Pharmaceutical Supply Chain from China Act (previously S. 3537) H.R. 6531, Medical Supplies for Pandemics Act H.R. 6876, To amend the Public Health Service Act to ensure that the contents of the Strategic National Stockpile remain in good working order and, as appropriate, conduct maintenance services on contents of the stockpile, and for other purposes. H.R. 6049, Medical Supply Chain Security Act H.R. 6062 - to amend certain provisions in the Federal Food, Drug, and Cosmetic Act relating to the discontinuance or interruption in the production of life-saving drugs so as to apply such provisions with respect to life-saving devices, and for other purposes H.R. 6080, Preventing Drug Shortages Act H.R. 6393, Strengthening America's Supply Chain and National Security Act H.R. 6660, Limit Ongoing Shortages and Stabilize Supply Act H.R. 6670, Prescription for American Drug Independence Act H.R. 6708, Securing Americas Medicine Cabinet Act H.R. 6885, Safe and Secure Medicine Supply for Hardworking Americans Act S. 2723, Mitigating Emergency Drug Shortages Act S. 3343, Medical Supply Chain Security Act S. 3780, Help Onshore Manufacturing Efficiencies for Drugs and Devices Act (HOME) Act S. 3781, Pharmaceutical Accountability, Responsibility, and Transparency (PART) Act S. 3942, Securing Americas Medical Supply Chain and Advancing the Production of Life Saving Medicines Act H.R. 6395, William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 - Issues related to pharmaceutical supply chains - Issues related to reporting on location of origin of pharmaceutical products - Issues related to drug shortages - Issues related to pharmaceutical manufacturing

H.R.2209 - Fixing Global Freeloading Act - Issues relating to trade policy and negotiations impacting the biopharmaceutical industry - Issues related to the United States-Mexico-Canada Agreement - Issues related to other Free Trade Agreements (Chile, Colombia, Peru, CAFTA-DR)

H.R.3 - Lower Drug Costs Now Act of 2019 S.977 - Transparent Drug Pricing Act of 2019 S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act H.R. 965, the CREATES Act H.R.269/S.1379, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22). S.1895, Lower Health Care Costs Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019. H.R.19, Lower Costs, More Cures Act of 2019. S. 3013, Encouraging Innovative Benefit Design to Lowes Costs for Seniors Act S. 3129, Lower Cost, More Cures Act of 2019 H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act -Issues related to Medicare and Medicaid coverage and reimbursement -Issues related to the 340B Drug Discount Program -Issues related to drug pricing -Medicare reimbursement for biosimilars -MACRA treatment and reimbursement of Part B drugs -Medicare payments for inpatient antimicrobials -Issues related to drug importation -Issues related to the International Pricing Index for Medicare Part B -Issues related to CMMI

H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019; H.R.6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (P.L.115-245) S. 3158, Department of Labor, Health & Human Services, and Education, and Related Agencies Appropriations Act of 2019; H.J.Res.31, Consolidated Appropriations Act, 2019 (P.L.116-6); FY 2020 H.R.3164, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure. H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020 and the FY2020 Consolidated measure. Reimbursement and vial size issues. H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act S. 3548 - CARES Act (Coronavirus Stimulus 3) - Issues related to FDA and HHS program funding for the FY20 Labor, HHS, Education and Related Agencies, and FY20 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills - Strategic National Stockpile (SNS) Funding and Oversight - Patient access to Part B medicines during the COVID-19 public health emergency

H.R.4549 - American Innovation and Competitiveness Act of 2019 - Issues related to the tax reform bill and implementation - Issues related to supply chain incentives

S. 2852 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act (No bill number yet) - Issues related to public health protection including influenza development and preparedness - Issues related to antimicrobial and antiviral research and product development - Issues related to novel coronavirus and COVID-19 research and product development

H.R. 6443, Securing the National Supply Chain Act H.R. 6630, Securing Americas Critical Minerals Supply Chain Act H.R. 6690, Bring Entrepreneurial Advancements To Consumers Here In North America Act H.R. 6713, Furthering Our Recovery With American Research and Development H.R. 6863, COVID-19 Accountability Act H.R. 6903, Bring American Companies Home Act H.R. 6930, To mitigate drug shortages and provide incentives for maintaining, expanding, and relocating the manufacturing of active pharmaceutical ingredients, excipients, medical diagnostic devices, pharmaceuticals, and personal protective equipment in the United States, and for other purposes. H.R. 7505, American Innovation Act H.R. 7527, To rescue domestic medical manufacturing activity by providing incentives in economically distressed areas of the United States and its possessions. H.R. 7537, Infectious Disease Therapies Research and Innovation Act H.R. 7555, More Cures Act H.R. 7556, Start-ups for Cures Act S. 3593, Furthering Our Recovery With American Research and Development S. 3945, Bring Entrepreneurial Advancements to Consumers Here In North America (BEAT CHINA) Act S. 3827, Medical Supplies for Pandemics Act H.R. 4710, Pharmaceutical Independence Long-Term Readiness Reform Act H.R. 6731, Securing Americas Pharmaceutical Supply Chain Act S. 3432, Securing Americas Medicine Cabinet [SAM-C] Act S. 3478, Commission on Americas Medical Security Act S. 3538, Strengthening America's Supply Chain and National Security Act S. 3635, Protecting our Pharmaceutical Supply Chain from China Act (previously S. 3537) H.R. 6531, Medical Supplies for Pandemics Act H.R. 6876, To amend the Public Health Service Act to ensure that the contents of the Strategic National Stockpile remain in good working order and, as appropriate, conduct maintenance services on contents of the stockpile, and for other purposes. H.R. 6049, Medical Supply Chain Security Act H.R. 6062 - to amend certain provisions in the Federal Food, Drug, and Cosmetic Act relating to the discontinuance or interruption in the production of life-saving drugs so as to apply such provisions with respect to life-saving devices, and for other purposes H.R. 6080, Preventing Drug Shortages Act H.R. 6393, Strengthening America's Supply Chain and National Security Act H.R. 6660, Limit Ongoing Shortages and Stabilize Supply Act H.R. 6670, Prescription for American Drug Independence Act H.R. 6708, Securing Americas Medicine Cabinet Act H.R. 6885, Safe and Secure Medicine Supply for Hardworking Americans Act S. 2723, Mitigating Emergency Drug Shortages Act S. 3343, Medical Supply Chain Security Act S. 3780, Help Onshore Manufacturing Efficiencies for Drugs and Devices Act (HOME) Act S. 3781, Pharmaceutical Accountability, Responsibility, and Transparency (PART) Act S. 3942, Securing Americas Medical Supply Chain and Advancing the Production of Life Saving Medicines Act H.R. 6395, William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 - Issues related to pharmaceutical supply chains - Issues related to reporting on location of origin of pharmaceutical products - Issues related to drug shortages - Issues related to pharmaceutical manufacturing

Foreign Investment Risk Review Modernization Act (FIRRMA) H.R. 5841/S. 2098 ​legislation that would reform the Committee on Foreign Investment in the United States (CFIUS)

S.4049 - National Defense Authorization Act for Fiscal Year 2021 H.R.2500 - National Defense Authorization Act for Fiscal Year 2021 H.R. 6395, William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 - Issues related to pharmaceutical supply chains and related security issues

S.659 - Biologic Patent Transparency Act S. 1227, Prescription Pricing for the People Act of 2019 S. 1224, Stop STALLING Act S.1416 - Affordable Prescriptions for Patients Act of 2019 H.R. 7296, Medications Affordable by Preventing Pandemic Price Gouging Act (MMAPPP) Act of 2020 H.R. 7288 Taxpayer Research and Coronavirus Knowledge (TRACK) Act H.R. 4398 Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 H.R. 1503, the Orange Book Transparency Act;consumer Access to Generic Drugs Act; and H.R. 965, the CREATES Act; - Intellectual property and process patent issues - Patent litigation reform - IPR process - Section 101 Reform - Compulsory licensing issues

H.J.Res.31, Consolidated Appropriations Act, 2019 (P.L.116-6); FY 2020 H.R.3164, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure. H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020 and the FY2020 Consolidated measure. Reimbursement and vial size issues. H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act S. 3548 - CARES Act (Coronavirus Stimulus 3) - Issues related to FDA and HHS program funding for the FY20 Labor, HHS, Education and Related Agencies, and FY20 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills - Strategic National Stockpile (SNS) Funding and Oversight - Patient access to Part B medicines during the COVID-19 public health emergency

H.R. 6443, Securing the National Supply Chain Act H.R. 6630, Securing Americas Critical Minerals Supply Chain Act H.R. 6690, Bring Entrepreneurial Advancements To Consumers Here In North America Act H.R. 6713, Furthering Our Recovery With American Research and Development H.R. 6863, COVID-19 Accountability Act H.R. 6903, Bring American Companies Home Act H.R. 6930, To mitigate drug shortages and provide incentives for maintaining, expanding, and relocating the manufacturing of active pharmaceutical ingredients, excipients, medical diagnostic devices, pharmaceuticals, and personal protective equipment in the United States, and for other purposes. H.R. 7505, American Innovation Act H.R. 7527, To rescue domestic medical manufacturing activity by providing incentives in economically distressed areas of the United States and its possessions. H.R. 7537, Infectious Disease Therapies Research and Innovation Act H.R. 7555, More Cures Act H.R. 7556, Start-ups for Cures Act S. 3593, Furthering Our Recovery With American Research and Development S. 3945, Bring Entrepreneurial Advancements to Consumers Here In North America (BEAT CHINA) Act S. 3827, Medical Supplies for Pandemics Act H.R. 4710, Pharmaceutical Independence Long-Term Readiness Reform Act H.R. 6731, Securing Americas Pharmaceutical Supply Chain Act S. 3432, Securing Americas Medicine Cabinet [SAM-C] Act S. 3478, Commission on Americas Medical Security Act S. 3538, Strengthening America's Supply Chain and National Security Act S. 3635, Protecting our Pharmaceutical Supply Chain from China Act (previously S. 3537) H.R. 6531, Medical Supplies for Pandemics Act H.R. 6876, To amend the Public Health Service Act to ensure that the contents of the Strategic National Stockpile remain in good working order and, as appropriate, conduct maintenance services on contents of the stockpile, and for other purposes. H.R. 6049, Medical Supply Chain Security Act H.R. 6062 - to amend certain provisions in the Federal Food, Drug, and Cosmetic Act relating to the discontinuance or interruption in the production of life-saving drugs so as to apply such provisions with respect to life-saving devices, and for other purposes H.R. 6080, Preventing Drug Shortages Act H.R. 6393, Strengthening America's Supply Chain and National Security Act H.R. 6660, Limit Ongoing Shortages and Stabilize Supply Act H.R. 6670, Prescription for American Drug Independence Act H.R. 6708, Securing Americas Medicine Cabinet Act H.R. 6885, Safe and Secure Medicine Supply for Hardworking Americans Act S. 2723, Mitigating Emergency Drug Shortages Act S. 3343, Medical Supply Chain Security Act S. 3780, Help Onshore Manufacturing Efficiencies for Drugs and Devices Act (HOME) Act S. 3781, Pharmaceutical Accountability, Responsibility, and Transparency (PART) Act S. 3942, Securing Americas Medical Supply Chain and Advancing the Production of Life Saving Medicines Act - Issues related to pharmaceutical supply chains - Issues related to reporting on location of origin of pharmaceutical products - Issues related to drug shortages - Issues related to pharmaceutical manufacturing

H.R.2209 - Fixing Global Freeloading Act - Issues relating to trade policy and negotiations impacting the biopharmaceutical industry - Issues related to the United States-Mexico-Canada Agreement

- Issues related to the tax reform bill and implementation - Issues related to supply chain incentives

S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act H.R.4100 - DISARM Act of 2019 S.340- CREATES Act of 2019 H.R. 2113 - The Prescription Drug STAR Act H.R. 1520, the Purple Book H.R. 1499, the Protecting Cok Continuity Act; H.R. 1503, the Orange Book Transparency Act;consumer Access to Generic Drugs Act; and H.R. 965, the CREATES Act; H.R.3: Lower Drug Costs Now Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S.551, REFUND Act of 2019 H.R. 6443, Securing the National Supply Chain Act H.R. 6630, Securing Americas Critical Minerals Supply Chain Act H.R. 6690, Bring Entrepreneurial Advancements To Consumers Here In North America Act H.R. 6713, Furthering Our Recovery With American Research and Development H.R. 6863, COVID-19 Accountability Act H.R. 6903, Bring American Companies Home Act H.R. 6930, To mitigate drug shortages and provide incentives for maintaining, expanding, and relocating the manufacturing of active pharmaceutical ingredients, excipients, medical diagnostic devices, pharmaceuticals, and personal protective equipment in the United States, and for other purposes. H.R. 7505, American Innovation Act H.R. 7527, To rescue domestic medical manufacturing activity by providing incentives in economically distressed areas of the United States and its possessions. H.R. 7537, Infectious Disease Therapies Research and Innovation Act H.R. 7555, More Cures Act H.R. 7556, Start-ups for Cures Act S. 3593, Furthering Our Recovery With American Research and Development S. 3945, Bring Entrepreneurial Advancements to Consumers Here In North America (BEAT CHINA) Act S. 3827, Medical Supplies for Pandemics Act H.R. 4710, Pharmaceutical Independence Long-Term Readiness Reform Act H.R. 6731, Securing Americas Pharmaceutical Supply Chain Act S. 3432, Securing Americas Medicine Cabinet [SAM-C] Act S. 3478, Commission on Americas Medical Security Act S. 3538, Strengthening America's Supply Chain and National Security Act S. 3635, Protecting our Pharmaceutical Supply Chain from China Act (previously S. 3537) H.R. 6531, Medical Supplies for Pandemics Act H.R. 6876, To amend the Public Health Service Act to ensure that the contents of the Strategic National Stockpile remain in good working order and, as appropriate, conduct maintenance services on contents of the stockpile, and for other purposes. H.R. 6049, Medical Supply Chain Security Act H.R. 6062 - to amend certain provisions in the Federal Food, Drug, and Cosmetic Act relating to the discontinuance or interruption in the production of life-saving drugs so as to apply such provisions with respect to life-saving devices, and for other purposes H.R. 6080, Preventing Drug Shortages Act H.R. 6393, Strengthening America's Supply Chain and National Security Act H.R. 6660, Limit Ongoing Shortages and Stabilize Supply Act H.R. 6670, Prescription for American Drug Independence Act H.R. 6708, Securing Americas Medicine Cabinet Act H.R. 6885, Safe and Secure Medicine Supply for Hardworking Americans Act S. 2723, Mitigating Emergency Drug Shortages Act S. 3343, Medical Supply Chain Security Act S. 3780, Help Onshore Manufacturing Efficiencies for Drugs and Devices Act (HOME) Act S. 3781, Pharmaceutical Accountability, Responsibility, and Transparency (PART) Act S. 3942, Securing Americas Medical Supply Chain and Advancing the Production of Life Saving Medicines Act - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency Medical Supply Chain - Issues related to pharmaceutical supply chains - Issues related to reporting on location of origin of pharmaceutical products - Issues related to drug shortages - Issues related to pharmaceutical manufacturing

S.659 - Biologic Patent Transparency Act S. 1227, Prescription Pricing for the People Act of 2019 S. 1224, Stop STALLING Act S.1416 - Affordable Prescriptions for Patients Act of 2019 H.R. 7296, Medications Affordable by Preventing Pandemic Price Gouging Act (MMAPPP) Act of 2020 H.R. 7288 Taxpayer Research and Coronavirus Knowledge (TRACK) Act - Intellectual property and process patent issues - Patent litigation reform - IPR process - Section 101 Reform - Compulsory licensing issues

- Foreign Investment Risk Review Modernization Act (FIRRMA) H.R. 5841/S. 2098 legislation that would reform the Committee on Foreign Investment in the United States (CFIUS)

S. 2852 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act - Issues related to public health protection including influenza development and preparedness - Issues related to antimicrobial and antiviral research and product development - Issues related to novel coronavirus and COVID-19 research and product development

S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. S.551, REFUND Act of 2019 HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program - Drug pricing issues - Prescription Drug User Fee Act reauthorization - Issues related to prescription drug value

S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act H.R.6294 - Re-Valuing Anti-Microbial Products (REVAMP) Act of 2018 S.340- CREATES Act of 2019 H.R. 2113 - The Prescription Drug STAR Act H.R. 1520, the Purple Book H.R. 1499, the Protecting Cok Continuity Act; H.R. 1503, the Orange Book Transparency Act;consumer Access to Generic Drugs Act; and H.R. 965, the CREATES Act; H.R.3: Lower Drug Costs Now Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S.551, REFUND Act of 2019 - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. -Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency

- Issues related to Foreign Agents Registration Act (FARA including Disclosing Foreign Influence Act -H.R. 4170/S. 2039

S.659 - Biologic Patent Transparency Act S. 1227, Prescription Pricing for the People Act of 2019 S. 1224, Stop STALLING Act S.1416 - Affordable Prescriptions for Patients Act of 2019 - Issues related to Intellectual property and process patent - Patent litigation reform - IPR process - Section 101 Reform - Compulsory licensing issues

H.R.2209 - Fixing Global Freeloading Act - Issues relating to trade policy and negotiations impacting the biopharmaceutical industry - Issues related to the United States-Mexico-Canada Agreement

- Issues related to the tax reform bill and implementation - Issues related to supply chain incentives

H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019; H.R.6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (P.L.115-245) S. 3158, Department of Labor, Health & Human Services, and Education, and Related Agencies Appropriations Act of 2019; H.J.Res.31, Consolidated Appropriations Act, 2019 (P.L.116-6); FY 2020 H.R.3164, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure. H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020 and the FY2020 Consolidated measure. Reimbursement and vial size issues. H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act S. 3548 - CARES Act (Coronavirus Stimulus 3) - Issues related to FDA and HHS program funding for the FY20 Labor, HHS, Education and Related Agencies, and FY20 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills - Strategic National Stockpile (SNS) Funding and Oversight - Patient access to Part B medicines during the COVID-19 public health emergency

- Foreign Investment Risk Review Modernization Act (FIRRMA) H.R. 5841/S. 2098 legislation that would reform the Committee on Foreign Investment in the United States (CFIUS)

Issues related to​ Foreign Agents Registration Act (FARA including​ Disclosing Foreign Influence Act -H.R. 4170/S. 2039

S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. S.551, REFUND Act of 2019 Issues - Drug pricing issues - Prescription Drug User Fee Act reauthorization - HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program - Issues related to prescription drug value

- Issues related to the tax reform bill and implementation

H.R.2209 - Fixing Global Freeloading Act - Issues relating to trade policy and negotiations impacting the biopharmaceutical industry - Issues related to the United States-Mexico-Canada Agreement

- Issues related to public health protection including influenza development and preparedness - Issues related to antimicrobial and antiviral research and product development

H.R.3 - Lower Drug Costs Now Act of 2019 S.977 - Transparent Drug Pricing Act of 2019 S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act H.R. 965, the CREATES Act H.R.269/S.1379, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22). S.1895, Lower Health Care Costs Act of 2019. S.2543, Prescription Drug Pricing Reduction Act of 2019. H.R.19, Lower Costs, More Cures Act of 2019. S.3013, Encourging Innovative Benefti Design to Lowes Costs for Seniors Act S. 3129, Lower Cost, More Cures Act of 2019 - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B

H.R.6294 - Re-Valuing Anti-Microbial Products (REVAMP) Act of 2018 S.340- CREATES Act of 2019 H.R. 2113 - The Prescription Drug STAR Act H.R. 1520, the Purple Book Continuity Act; H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act; and H.R. 965, the CREATES Act; H.R.3: Lower Drug Costs Now Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S.551, REFUND Act of 2019 -Issues related to the 340B Drug Discount Program -Issues relating to drug pricing -Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. -Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. -General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. -Issues related to healthcare legislation

S.1416 - Affordable Prescriptions for Patients Act of 2019 S.659 - Biologic Patent Transparency Act S. 1227, Prescription Pricing for the People Act of 2019 S. 1224, Stop STALLING Act - Intellectual property and process patent issues - Patent litigation reform - IPR process - Section 101 Reform

H.R. 4710 - 340B Protecting Access for the Underserved and Safety-Net Entities (PAUSE) Act S. 2312 - The Helping Ensure Low-income Patients have Access to Care and Treatment Act S. 2453 - Ensuring the Value of the 340B Program Act of 2018 HR 4392 - Reversing the HOPPS rule reimbursement cut to 340B hospitals HR 5598 - 340B Optimization Act HR 2889 - Closing Loopholes for Orphan Drugs Act HR 6240 - Drug Discount Accountability Act (user fees) H.R.6071 - SERV Communities Act of 2018 S.204/H.R.878, Trickett-Wendler Right to Try Act of 2017 P.L.109-417, Pandemic and All-Hazards Preparedness Act (PAHPA) S.2852 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 H.R.6294 - Re-Valuing Anti-Microbial Products (REVAMP) Act of 2018 S.974 - CREATES Act of 2017 H.R. 2113 - The Prescription Drug STAR Act H.R. 1520, the Purple Book Continuity Act; H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act; and H.R. 965, the CREATES Act; -Issues related to the 340B Drug Discount Program -Issues relating to drug pricing -Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. -Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. -General education about policies impacting pharmaceutical development, approval, reimbursement and pricing.

H.R.3 - Lower Drug Costs Now Act of 2019 Prescription Drug Pricing Reduction Act (PDPRA) of 2019 S.977 - Transparent Drug Pricing Act of 2019 H.R. 4710 - 340B Protecting Access for the Underserved and Safety-Net Entities Act (340B PAUSE Act) S. 2312 - The Helping Ensure Low-income Patients have Access to Care and Treatment Act S. 2453 - Ensuring the Value of the 340B Program Act of 2018 Part D Medicare Program (including Coverage Gap and other offsets in H.R.1892/P.L.115-123, Bipartisan Budget Act of 2018). HR 4392 - reversing the HOPPS rule reimbursement cut to 340B hospitals HR 5598 - 340B Optimization Act HR 2889 - Closing Loopholes for Orphan Drugs Act HR 6071 - SERV Communities Act HR 6240 - Drug Discount Accountability Act (user fees) S.3787 - DISARM Act of 2018 H.R. 7077, the Restoring the Patients Voice Act S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act H.R. 965, the CREATES Act H.R.269/S.1379, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22). S.1895, Lower Health Care Costs Act of 2019. -Issues related to Medicare and Medicaid coverage and reimbursement -Issues related to the 340B Drug Discount Program -Issues related to drug pricing -Medicare reimbursement for biosimilars -MACRA treatment and reimbursement of Part B drugs -Medicare payments for inpatient antimicrobials -Issues related to drug importation

- Foreign Investment Risk Review Modernization Act (FIRRMA) H.R. 5841/S. 2098 ​legislation that would reform the Committee on Foreign Investment in the United States (CFIUS)

S. 2852 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 - Issues related to public health protection including influenza development and preparedness - Issues related to antimicrobial and antiviral research and product development

H.R.1892, Bipartisan Budget Act of 2018 H.R.1625, Consolidated Appropriations Act, 2018 H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019; H.R.6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (P.L.115-245) S. 3158, Department of Labor, Health & Human Services, and Education, and Related Agencies Appropriations Act of 2019; H.J.Res.31, Consolidated Appropriations Act, 2019 (P.L.116-6); FY 2020 H.R.3164, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure. H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020 and he FY2020 Consolidated measure. Reimbursement and vial size issues. Issues related to FDA and HHS program funding for the FY20 Labor, HHS, Education and Related Agencies, and FY20 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills

H.R.2209 - Fixing Global Freeloading Act - Issues relating to trade policy and negotiations impacting the biopharmaceutical industry

Issues related to​ Foreign Agents Registration Act (FARA including​ Disclosing Foreign Influence Act -H.R. 4170/S. 2039

S. 2852 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 - Issues related to public health protection including influenza development and preparedness - Issues related to antimicrobial and antiviral research and product development

H.R.1892, Bipartisan Budget Act of 2018 H.R.1625, Consolidated Appropriations Act, 2018 H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019; H.R.6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (P.L.115-245) S. 3158, Department of Labor, Health & Human Services, and Education, and Related Agencies Appropriations Act of 2019; H.J.Res.31, Consolidated Appropriations Act, 2019 (P.L.116-6); FY 2020 H.R.3164, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure. H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020 and he FY2020 Consolidated measure. Reimbursement and vial size issues. - Issues related to FDA and HHS program funding for the FY20 Labor, HHS, Education and Related Agencies, and FY20 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills

HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program - Drug pricing issues - Prescription Drug User Fee Act reauthorization

S.977 - Transparent Drug Pricing Act of 2019 H.R. 4710 - 340B Protecting Access for the Underserved and Safety-Net Entities Act (340B PAUSE Act) S. 2312 - The Helping Ensure Low-income Patients have Access to Care and Treatment Act S. 2453 - Ensuring the Value of the 340B Program Act of 2018 Part D Medicare Program (including Coverage Gap and other offsets in H.R.1892/P.L.115-123, Bipartisan Budget Act of 2018). HR 4392 - reversing the HOPPS rule reimbursement cut to 340B hospitals HR 5598 - 340B Optimization Act HR 2889 - Closing Loopholes for Orphan Drugs Act HR 6071 - SERV Communities Act HR 6240 - Drug Discount Accountability Act (user fees) S.3787 - DISARM Act of 2018 H.R. 7077, the Restoring the Patients Voice Act S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act H.R. 965, the CREATES Act H.R.269/S.1379, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22). S.1895, Lower Health Care Costs Act of 2019. - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part D

H.R.1, Tax Reform Act of 2017 (Public Law No. 115-97) H.R.88, Retirement, Savings, and Other Tax Relief Act of 2018 and Taxpayer First Act of - Issues related to the tax reform bill and implementation

S.1416 - Affordable Prescriptions for Patients Act of 2019 S.659 - Biologic Patent Transparency Act S. 1227, Prescription Pricing for the People Act of 2019 S. 1224, Stop STALLING Act - Intellectual property and process patent issues - Patent litigation reform - IPR process - Section 101 Reform

H.R.3 - Lower Drug Costs Now Act of 2019 S.977 - Transparent Drug Pricing Act of 2019 S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act H.R. 965, the CREATES Act H.R.269/S.1379, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22). S.1895, Lower Health Care Costs Act of 2019. S.2543, Prescription Drug Pricing Reduction Act of 2019. H.R.19, Lower Costs, More Cures Act of 2019. S.3013, Encourging Innovative Benefti Design to Lowes Costs for Seniors Act S. 3129, Lower Cost, More Cures Act of 2019 - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B

Issues related to​ Foreign Agents Registration Act (FARA including​ Disclosing Foreign Influence Act -H.R. 4170/S. 2039

S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. S.551, REFUND Act of 2019 Issues - Drug pricing issues - Prescription Drug User Fee Act reauthorization - HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program - Issues related to prescription drug value

H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019; H.R.6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (P.L.115-245) S. 3158, Department of Labor, Health & Human Services, and Education, and Related Agencies Appropriations Act of 2019; H.J.Res.31, Consolidated Appropriations Act, 2019 (P.L.116-6); FY 2020 H.R.3164, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure. H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020 and he FY2020 Consolidated measure. Reimbursement and vial size issues. Issues related to FDA and HHS program funding for the FY20 Labor, HHS, Education and Related Agencies, and FY20 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills

H.R.2209 - Fixing Global Freeloading Act - Issues relating to trade policy and negotiations impacting the biopharmaceutical industry - Issues related to the United States-Mexico-Canada Agreement

H.R.6294 - Re-Valuing Anti-Microbial Products (REVAMP) Act of 2018 S.340- CREATES Act of 2019 H.R. 2113 - The Prescription Drug STAR Act H.R. 1520, the Purple Book Continuity Act; H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act; and H.R. 965, the CREATES Act; H.R.3: Lower Drug Costs Now Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S.551, REFUND Act of 2019 -Issues related to the 340B Drug Discount Program -Issues relating to drug pricing -Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. -Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. -General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. -Issues related to healthcare legislation

HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program - Drug pricing issues - Prescription Drug User Fee Act reauthorization

H.R.2209 - Fixing Global Freeloading Act - Issues relating to trade policy and negotiations impacting the biopharmaceutical industry

H.R. 4710 - 340B Protecting Access for the Underserved and Safety-Net Entities (PAUSE) Act S. 2312 - The Helping Ensure Low-income Patients have Access to Care and Treatment Act S. 2453 - Ensuring the Value of the 340B Program Act of 2018 HR 4392 - Reversing the HOPPS rule reimbursement cut to 340B hospitals HR 5598 - 340B Optimization Act HR 2889 - Closing Loopholes for Orphan Drugs Act HR 6240 - Drug Discount Accountability Act (user fees) H.R.6071 - SERV Communities Act of 2018 S.204/H.R.878, Trickett-Wendler Right to Try Act of 2017 P.L.109-417, Pandemic and All-Hazards Preparedness Act (PAHPA) S.2852 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 H.R.6294 - Re-Valuing Anti-Microbial Products (REVAMP) Act of 2018 S.974 - CREATES Act of 2017 H.R. 2113 - The Prescription Drug STAR Act H.R. 1520, the Purple Book Continuity Act; H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act; and H.R. 965, the CREATES Act; -Issues related to the 340B Drug Discount Program -Issues relating to drug pricing -Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. -Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. -General education about policies impacting pharmaceutical development, approval, reimbursement and pricing.

H.R.3 - Lower Drug Costs Now Act of 2019 Prescription Drug Pricing Reduction Act (PDPRA) of 2019 S.977 - Transparent Drug Pricing Act of 2019 H.R. 4710 - 340B Protecting Access for the Underserved and Safety-Net Entities Act (340B PAUSE Act) S. 2312 - The Helping Ensure Low-income Patients have Access to Care and Treatment Act S. 2453 - Ensuring the Value of the 340B Program Act of 2018 Part D Medicare Program (including Coverage Gap and other offsets in H.R.1892/P.L.115-123, Bipartisan Budget Act of 2018). HR 4392 - reversing the HOPPS rule reimbursement cut to 340B hospitals HR 5598 - 340B Optimization Act HR 2889 - Closing Loopholes for Orphan Drugs Act HR 6071 - SERV Communities Act HR 6240 - Drug Discount Accountability Act (user fees) S.3787 - DISARM Act of 2018 H.R. 7077, the Restoring the Patients Voice Act S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act H.R. 965, the CREATES Act H.R.269/S.1379, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22). S.1895, Lower Health Care Costs Act of 2019. -Issues related to Medicare and Medicaid coverage and reimbursement -Issues related to the 340B Drug Discount Program -Issues related to drug pricing -Medicare reimbursement for biosimilars -MACRA treatment and reimbursement of Part B drugs -Medicare payments for inpatient antimicrobials -Issues related to drug importation

H.R.1, Tax Reform Act of 2017 (Public Law No. 115-97) H.R.88, Retirement, Savings, and Other Tax Relief Act of 2018 and Taxpayer First Act of - Issues related to the tax reform bill and implementation

S. 2852 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 - Issues related to public health protection including influenza development and preparedness - Issues related to antimicrobial and antiviral research and product development

S.1416 - Affordable Prescriptions for Patients Act of 2019 S.659 - Biologic Patent Transparency Act S. 1227, Prescription Pricing for the People Act of 2019 S. 1224, Stop STALLING Act - Intellectual property and process patent issues - Patent litigation reform - IPR process - Section 101 Reform

Issues related to​ Foreign Agents Registration Act (FARA including​ Disclosing Foreign Influence Act -H.R. 4170/S. 2039

H.R.2209 - Fixing Global Freeloading Act - Issues relating to trade policy and negotiations impacting the biopharmaceutical industry

H.R.1892, Bipartisan Budget Act of 2018 H.R.1625, Consolidated Appropriations Act, 2018 H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019; H.R.6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (P.L.115-245) S. 3158, Department of Labor, Health & Human Services, and Education, and Related Agencies Appropriations Act of 2019; H.J.Res.31, Consolidated Appropriations Act, 2019 (P.L.116-6); FY 2020 H.R.3164, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure. H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020 and he FY2020 Consolidated measure. Reimbursement and vial size issues. - Issues related to FDA and HHS program funding for the FY20 Labor, HHS, Education and Related Agencies, and FY20 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills

S.977 - Transparent Drug Pricing Act of 2019 H.R. 4710 - 340B Protecting Access for the Underserved and Safety-Net Entities Act (340B PAUSE Act) S. 2312 - The Helping Ensure Low-income Patients have Access to Care and Treatment Act S. 2453 - Ensuring the Value of the 340B Program Act of 2018 Part D Medicare Program (including Coverage Gap and other offsets in H.R.1892/P.L.115-123, Bipartisan Budget Act of 2018). HR 4392 - reversing the HOPPS rule reimbursement cut to 340B hospitals HR 5598 - 340B Optimization Act HR 2889 - Closing Loopholes for Orphan Drugs Act HR 6071 - SERV Communities Act HR 6240 - Drug Discount Accountability Act (user fees) S.3787 - DISARM Act of 2018 H.R. 7077, the Restoring the Patients Voice Act S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act H.R. 965, the CREATES Act H.R.269/S.1379, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22). S.1895, Lower Health Care Costs Act of 2019. - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part D

H.R. 4710 - 340B Protecting Access for the Underserved and Safety-Net Entities (PAUSE) Act S. 2312 - The Helping Ensure Low-income Patients have Access to Care and Treatment Act S. 2453 - Ensuring the Value of the 340B Program Act of 2018 HR 4392 - Reversing the HOPPS rule reimbursement cut to 340B hospitals HR 5598 - 340B Optimization Act HR 2889 - Closing Loopholes for Orphan Drugs Act HR 6240 - Drug Discount Accountability Act (user fees) H.R.6071 - SERV Communities Act of 2018 S.204/H.R.878, Trickett-Wendler Right to Try Act of 2017 P.L.109-417, Pandemic and All-Hazards Preparedness Act (PAHPA) S.2852 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 H.R.6294 - Re-Valuing Anti-Microbial Products (REVAMP) Act of 2018 S.974 - CREATES Act of 2017 H.R. 2113 - The Prescription Drug STAR Act H.R. 1520, the Purple Book Continuity Act; H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act; and H.R. 965, the CREATES Act; - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing.

S. 2852 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 - Issues related to public health protection including influenza development and preparedness - Issues related to antimicrobial and antiviral research and product development

S.1416 - Affordable Prescriptions for Patients Act of 2019 S.659 - Biologic Patent Transparency Act S. 1227, Prescription Pricing for the People Act of 2019 S. 1224, Stop STALLING Act - Intellectual property and process patent issues - Patent litigation reform - IPR process - Section 101 Reform

- Drug pricing issues - Prescription Drug User Fee Act reauthorization - HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program

- Issues relating to trade policy and negotiations impacting the biopharmaceutical industry

H.R.1892, Bipartisan Budget Act of 2018 H.R.1625, Consolidated Appropriations Act, 2018 H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019; H.R.6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (P.L.115-245) S. 3158, Department of Labor , Health & Human Services, and Education, and Related Agencies Appropriations Act of 2019; H.J.Res.31, Consolidated Appropriations Act, 2019 (P.L.116-6); FY 2020 - Issues related to FDA and HHS program funding for the FY19 Labor, HHS, Education and Related Agencies, and FY19 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills

S.3738 - Hatch-Waxman Integrity Act of 2018 - Intellectual property and process patent issues - Patent litigation reform - IPR process

H.R. 4710 - 340B Protecting Access for the Underserved and Safety-Net Entities (PAUSE) Act S. 2312 - The Helping Ensure Low-income Patients have Access to Care and Treatment Act S. 2453 - Ensuring the Value of the 340B Program Act of 2018 HR 4392 - Reversing the HOPPS rule reimbursement cut to 340B hospitals HR 5598 - 340B Optimization Act HR 2889 - Closing Loopholes for Orphan Drugs Act HR 6240 - Drug Discount Accountability Act (user fees) H.R.6071 - SERV Communities Act of 2018 S.204/H.R.878, Trickett-Wendler Right to Try Act of 2017 P.L.109-417, Pandemic and All-Hazards Preparedness Act (PAHPA) S.2852 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 H.R.6294 - Re-Valuing Anti-Microbial Products (REVAMP) Act of 2018 S.974 - CREATES Act of 2017 H.R. 2113 - The Prescription Drug STAR Act H.R. 1520, the Purple Book Continuity Act; H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act; and H.R. 965, the CREATES Act; - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety, and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement, and pricing. - Issues related to healthcare legislation

- Foreign Investment Risk Review Modernization Act (FIRRMA) H.R. 5841/S. 2098 ​legislation that would reform the Committee on Foreign Investment in the United States (CFIUS)

- Issues related to​ Foreign Agents Registration Act (FARA including​ Disclosing Foreign Influence Act -H.R. 4170/S. 2039

- Drug pricing issues - Prescription Drug User Fee Act reauthorization - HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program

H.R. 4710 - 340B Protecting Access for the Underserved and Safety-Net Entities (PAUSE) Act S. 2312 - The Helping Ensure Low-income Patients have Access to Care and Treatment Act S. 2453 - Ensuring the Value of the 340B Program Act of 2018 HR 4392 - Reversing the HOPPS rule reimbursement cut to 340B hospitals HR 5598 - 340B Optimization Act HR 2889 - Closing Loopholes for Orphan Drugs Act HR 6240 - Drug Discount Accountability Act (user fees) H.R.6071 - SERV Communities Act of 2018 S.204/H.R.878, Trickett-Wendler Right to Try Act of 2017 P.L.109-417, Pandemic and All-Hazards Preparedness Act (PAHPA) S.2852 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 H.R.6294 - Re-Valuing Anti-Microbial Products (REVAMP) Act of 2018 S.974 - CREATES Act of 2017 - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation

S. 2852 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 - Issues related to public health protection including influenza development and preparedness - Issues related to Right to Try - Issues related to antimicrobial and antiviral research and product development

S.3738 - Hatch-Waxman Integrity Act of 2018 : - Intellectual property and process patent issues - Patent litigation reform - IPR process

- Foreign Investment Risk Review Modernization Act (FIRRMA) H.R. 5841/S. 2098 ​legislation that would reform the Committee on Foreign Investment in the United States (CFIUS)

H.R.1892, Bipartisan Budget Act of 2018 H.R.1625, Consolidated Appropriations Act, 2018 H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019; H.R.6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (P.L.115-245) S. 3158, Department of Labor , Health & Human Services, and Education, and Related Agencies Appropriations Act of 2019; - Issues related to FDA and HHS program funding for the FY19 Labor, HHS, Education and Related Agencies, and FY19 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills

Issues related to​ Foreign Agents Registration Act (FARA including​ Disclosing Foreign Influence Act -H.R. 4170/S. 2039

Issues relating to trade policy and negotiations impacting the biopharmaceutical industry

Issues related to​ Foreign Agents Registration Act (FARA​), including​ Disclosing Foreign Influence Act -H.R. 4170/S. 2039

H.R.1, Tax Reform Act of 2017 (Public Law No. 115-97) Issues related to the tax reform bill and implementation

Foreign Investment Risk Review Modernization Act (FIRRMA)​ H.R. 5841/S. 2098 ​, legislation that would reform the Committee on Foreign Investment in the United States (CFIUS)

S.3158/H.R.6470, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2019; H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019; H.R. 1892, the Bipartisan Budget H.R. 1625, Consolidated Appropriation Act H.R.6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (P.L.115-245); Issues related to FDA and HHS program funding for the FY19 Labor, HHS, Education and Related Agencies, and FY19 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills Issues related to Direct-To-Consumer Advertising, 340B, biosimilars, and public health

H.R. 4710 - 340B Protecting Access for the Underserved and Safety-Net Entities (PAUSE) Act S. 2312 - The Helping Ensure Low-income Patients have Access to Care and Treatment Act S. 2453 - Ensuring the Value of the 340B Program Act of 2018 HR 4392 - Reversing the HOPPS rule reimbursement cut to 340B hospitals HR 5598 - 340B Optimization Act HR 2889 - Closing Loopholes for Orphan Drugs Act HR 6240 - Drug Discount Accountability Act (user fees) H.R.6071 - SERV Communities Act of 2018 P.L.109-417, Pandemic and All-Hazards Preparedness Act (PAHPA) S.2852 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 H.R. 6378 - To reauthorize certain programs under the Pandemic and All-Hazards Preparedness Reauthorization Act H.R.6294 - Re-Valuing Anti-Microbial Products (REVAMP) Act of 2018 S.974 - CREATES Act of 2017 Issues related to the 340B Drug Discount Program Issues relating to drug pricing, reimbursement, step therapy, anti-kickback statute, biosimilars Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. General education about policies impacting pharmaceutical development, approval, reimbursement and pricing

Drug Pricing Issues HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program

Intellectual property and process patent issues Patent litigation reform

S. 2852 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 H.R. 6378 - To reauthorize certain programs under the Pandemic and All-Hazards Preparedness Reauthorization Act Issues related to public health protection including influenza development and preparedness Issues related to antimicrobial and antiviral research and product development

H.R. 3358/S 1771 Departments of Labor, Health, and Human Services, and Education, and Related Agencies Appropriations Act, 2018 H.R.3268/S.1603, Agriculture, Rural Development, Food, and Drug Administration, and Related Agencies Appropriations Act, 2018 H.R.1370, Further Additional Continuing Appropriations Act, 2018 H.R.1892, Bipartisan Budget Act of 2018 H.R.1625, Consolidated Appropriations Act, 2018 Issues related to FDA and HHS program funding for the FY18 Labor, HHS, Education and Related Agencies, and FY18 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills Issues related to FDA and HHS program funding for the FY19 Labor, HHS, Education and Related Agencies, and FY19 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills

Intellectual property and process patent issues Patent litigation reform

H.R.1, Tax Reform Act of 2017 (Public Law No. 115-97) Issues related to the tax reform bill and implementation

S. 2852 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 Issues related to public health protection including influenza development and preparedness Issues related to Right to Try Issues related to antimicrobial and antiviral research and product development

Drug Pricing Issues HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program

Foreign Investment Risk Review Modernization Act (FIRRMA)​ H.R. 5841/S. 2098 ​, legislation that would reform the Committee on Foreign Investment in the United States (CFIUS)

Issues related to​ Foreign Agents Registration Act (FARA​), including​ Disclosing Foreign Influence Act -H.R. 4170/S. 2039

Issues relating to trade policy and negotiations impacting the biopharmaceutical industry

H.R. 4710 - 340B Protecting Access for the Underserved and Safety-Net Entities Act. S. 2312 - The Helping Ensure Low-income Patients have Access to Care and Treatment Act S. 2453 - Ensuring the Value of the 340B Program Act of 2018 Part D Medicare Program (including Coverage Gap and other offsets in H.R.1892/P.L.115-123, Bipartisan Budget Act of 2018). Issues related to Medicare and Medicaid coverage and reimbursement Issues related to the 340B Drug Discount Program Issues related to RX drug pricing Medicare reimbursement for biosimilars MACRA treatment and reimbursement of Part B drugs Medicare payments for inpatient antimicrobials

Drug Pricing Issues Prescription Drug User Fee Act reauthorization. HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program

H.R.3358/S.1771, Departments of Labor, Health, and Human Services, and Education, and Related Agencies Appropriations Act, 2018 H.R.3268/S.1603, Agriculture, Rural Development, Food, and Drug Administration, and Related Agencies Appropriations Act, 2018 H.R.1370, Further Additional Continuing Appropriations Act, 2018 H.R.1892, Bipartisan Budget Act of 2018 H.R.1625, Consolidated Appropriations Act, 2018 Issues related to FDA and HHS program funding for the FY18 Labor, Health and Human Services, and Education and Related Agencies, and FY18 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills Issues related to FDA and HHS program funding for the FY19 Labor, Health and Human Services, and Education and Related Agencies, and FY18 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills

Trade Policy Issues. Trade Negotiations.

Medicare payment policies for Part B drugs. HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program CHIP reauthorization and Medicare Extenders package. Issues related to Medicare and Medicaid coverage and reimbursement; Issues relating to biosimilar reimbursement; Issues related to RX drug pricing. Medicare payment for inpatient antimicrobial therapy.

General tax issues. H.R. 1, Tax Cuts and Jobs Act. Tax Reform Act of 2017 - Issues related to tax reform

Medicare payment policies for Part B drugs. HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program CHIP reauthorization and Medicare Extenders package. Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 S.204/H.R.878, Trickett Wendler Right to Try Act of 2017 H.J.Res.123, Making further continuing appropriations for fiscal year 2018, and for other purposes H.J.Res.124, Making further additional continuing appropriations for fiscal year 2018, and for other purposes H.R.1370, Further Additional Continuing Appropriations Act, 2018 Pharmaceutical benefits for TRICARE beneficiaries Issues related to pharmaceutical drug pricing Development of policies to advance the antimicrobial research and novel product development environment, including advancing new market incentives. Pharmaceutical distribution and supply chain security American Health Care Act of 2017 Issues relating to biosimilar reimbursement

Medicare payment policies for Part B drugs. HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program CHIP reauthorization and Medicare Extenders package. Issues related to Medicare and Medicaid coverage and reimbursement; Issues relating to biosimilar reimbursement; Issues related to RX drug pricing. Medicare payment for inpatient antimicrobial therapy.

General tax issues. H.R. 1, Tax Cuts and Jobs Act. Tax Reform Act of 2017 - Issues related to tax reform

Drug Pricing Issues Prescription Drug User Fee Act reauthorization. HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program

Issues related to FDA and HHS program funding in the FY18 Labor, Health and Human Services, and Education and Related Agencies, and FY18 Agriculture, Rural Development, Food and Drug Administrations, Related Agencies Appropriation bills

Trade Policy Issues. Trade Negotiations.

H.R. 1628 American Health Care Act of 2017; Better Care Reconciliation Act; General education, guidance and strategic counsel about policies impacting pharmaceutical development, approval and reimbursement; H.R. 2430/S. 934, FDA Reauthorization Act of 2017 General education about FDA approval policies including pediatric trial design, and right-to-try proposals Advocated to include market incentives for antimicrobials in H.R. 2430 / S. 934 - FDA Reauthorization Act of 2017 Implementation issues related to the Pharmaceutical Quality, Security and Accountability Act (P.L. 113-54) Issues related to drug pricing Education around issues relating to the 340B Drug Discount Program Issues related to FDA and HHS program funding in the FY18 Labor, Health and Human Services, and Education and Related Agencies, and FY18 Agriculture, Rural Developments, Food and Drug Administrations, and Related Agencies Appropriation bills

Issues relating to drug pricing Education on policies pertaining to the 340B Drug Discount Program

Intellectual property and process patent issues. General IP issues. Patent litigation reform.

340B Drug Discount Program.

Implementation of Medicare pharmaceutical coverage and reimbursement issues Policies relating to 340B Drug Discount Program Issues relating to the repeal and replacement of the Affordable Care Act (HR 1628, The American Health Care Act). Medicare Part B reimbursement issues for physicians and implementation of related provisions of MACRA Payment policies for prescription drugs

Trade negotiations, Transatlantic Trade and Investment Partnership (TTIP), NAFTA. Issues related to trade policy.

Issues related to FDA and HHS program funding in the FY17 Labor, Health and Human Services, and Education and Related Agencies, and FY17 Agriculture, Rural Developments, Food and Drug Administrations, and Related Agencies Appropriations bills. FY2018, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; FY2018, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; H.R.244, Consolidated Appropriations Act 2017 (P.L.115-31); vial size issues. Issues related to establishing the budget for the United States Government for FY 2018, Bipartisan Budget Act of 2015

Intellectual property and process patent issues. General IP issues. Patent litigation reform.